THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company involved in the development and commercialization of cell therapies, has named Mark Pittenger, Ph.D, to its Scientific Advisory Board (SAB). Dr. Pittenger, who was Vice President, Research, and part of the senior management team at Osiris Therapeutics, Inc. until 2005, is a pioneer in the stem cell and regenerative medicine fields. He currently serves as a consultant to companies developing cellular therapeutics, including stem cell technologies. He is a Senior Director at Life Sciences Technologies Partners, and an adjunct Assistant Professor at Johns Hopkins University.
